CBRT19124/ ACNS1721 / Angela Girvin
Basic Study Information
Purpose:Location: University of Rochester
This phase II trial studies how well veliparib, radiation therapy, and temozolomide
work in treating patients with newly diagnosed malignant glioma without H3 K27M or
BRAFV600 mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are
proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep
PARP from working, so tumor cells can't repair themselves, and they may stop growing.
Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs
used in chemotherapy, such as temozolomide, work in different ways to stop the growth
of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide
may work better in treating patients with newly diagnosed malignant glioma without
H3 K27M or BRAFV600 mutations compared to radiation therapy and temozolomide alone.
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search